President Trump said all generic drugs imported into the United States will have
zero tariffs for two years from Aug. 1, 2026. Thereafter tariffs will be raised
to 100% for one year and then to 200% thereafter; the move is aimed at
repatriating generic drug production and penalizing firms that fail to establish
domestic production facilities and equipment within the required timeframe.
Existing tariff and trade policies for patented, brand and innovative drugs will
remain unchanged. U.S. construction of pharmaceutical manufacturing capacity is
proceeding at an unprecedented scale nationwide, he said.
